
|Articles|June 16, 2020
Pratia and KFGN Join Forces
Advertisement
Pratia Inc has claimed 40% shares in KFGN, with an overall investment plan that assumes increased shareholding up to a clear majority position in the upcoming years. Dr. Ole Dammann will continue his leadership as CEO of KFGN. Additionally, as a Board Member of Pratia, he will support international growth of Site Network.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Praxis Reports Positive Phase III Results for Ulixacaltamide in Essential Tremor
2
Imfinzi Plus FLOT Significantly Improves Overall Survival in Gastric and Gastroesophageal Cancer
3
Applied Clinical Trials: October 2025 Interactive Digital Edition
4
Setting the Limits of Autonomy with Autonomous Agents for Clinical Research
5